Physician

William Surbeck, M.D.

According to 2025 Medicare claims, William Surbeck, M.D. (NPI: 1154382711) practices rheumatology in the Tulsa, OK market, with the plurality of this provider's patient population coming from Tulsa, OK. This provider's primary affiliated billing organization is TULSA BONE & JOINT ASSOCIATES PC (NPI: 1154373132; TIN: 731551429) and primary practice location at 74146-5826.

Surbeck's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 518 traditional Medicare patients, billed 202,000 HCPCS/CPT codes, and received $1,911,850 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 5,624 prescription claims across 626 beneficiaries totaling $5,478,642 in drug costs, led by Humira(Cf) Pen (Adalimumab). 2019 DME data shows 23 claims. Open Payments data shows 152 records totaling $2,904. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,783,794 to $5,478,642. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	591	118,506	$1,994,063
2016	627	113,804	$1,790,296
2017	671	108,821	$2,042,916
2018	687	115,655	$2,059,105
2019	676	151,754	$2,261,455
2020	619	174,466	$2,125,667
2021	571	160,249	$1,939,140
2022	613	188,313	$2,113,834
2023	577	204,574	$2,080,682
2024	518	202,000	$1,911,850

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	597	5,538	$1,783,794
2016	600	5,671	$2,052,635
2017	647	6,192	$2,660,416
2018	669	6,327	$2,884,603
2019	634	5,900	$3,700,547
2020	615	5,767	$3,810,986
2021	610	5,740	$4,427,845
2022	672	5,944	$5,200,653
2023	662	5,952	$6,477,340
2024	626	5,624	$5,478,642

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	23	$452
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	53	272	$80
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	460	1,044	$79
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	72	86	$61
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	47	321	$41
96372	Injection of drug or substance under skin or into muscle	67	529	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	164	4,686	$1,388,566
Enbrel Sureclick	Etanercept	148	4,704	$1,256,412
Rinvoq	Upadacitinib	71	2,280	$474,040
Humira(Cf)	Adalimumab	28	784	$273,412
Xeljanz Xr	Tofacitinib Citrate	44	1,320	$249,989

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	152	$2,904	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for William Surbeck, M.D.?

Tedicare shows public-source Medicare data for William Surbeck, M.D. (NPI 1154382711), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does William Surbeck, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to William Surbeck, M.D.?

William Surbeck, M.D. is linked to TULSA BONE & JOINT ASSOCIATES PC (billing NPI 1154373132) in the available physician profile data.

Does William Surbeck, M.D. have Open Payments data?

William Surbeck, M.D. has 152 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.